A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)
Key facts
- Who runs it
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Where
- Miami Lakes and Spartanburg, United StatesSee the 4 sitesAlso in 1 other country, 2 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 400 people, planned
- Started
- 29 Oct 2025
- Expected to end
- 31 Jul 2027
- Type of study
- Interventional
- Treatments tested
- MK-1406 Injection
- Record updated
- 20 August 2026
Who can take part
- Age
- 18 years to 66 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- The main inclusion criteria include but are not limited to the following:
- Be in stable health
- Has previously completed participation in study CD388.SQ.2.05/MK-1406-004, and received a subcutaneous (SC) CD388/MK-1406 dose of either 150 mg, 300 mg or 450 mg
Who cannot take part
- Have a contraindication to subcutaneous (SQ) injections and venipunctures (eg, bleeding disorders)
- Has a known or suspected allergy or history of anaphylaxis or other serious adverse events (SAEs) to zanamivir (following administration of inhaled or intravenous formulations), monoclonal antibodies, or any of the components of CD388/MK-1406
- The main exclusion criteria include but are not limited to the following:
Where in United States
Also in 1 other country, 2 sites
- Floridian Clinical ResearchMiami Lakes, United States
- Floridian Clinical Research (Site 0102)Miami Lakes, United States
- Spartanburg Medical ResearchSpartanburg, United States
- Spartanburg Medical Research (Site 0101)Spartanburg, United States
About the trial
What the trial wants to find out
The goal of this clinical study is to learn if giving repeated annual doses of MK-1406 (CD388) is safe and how the body reacts to it in healthy adults who have already received one dose without serious side effects. The study aims to determine if the body makes antibodies against MK-1406 after repeated doses, which might affect how the drug works or how safe it is, and to better understand the safety and tolerability of repeated doses. Participants will receive two doses of MK-1406 over two years and be monitored for 18 months. Researchers will check for immune responses against the drug, watch for any side effects, and measure how the drug behaves in the body over time. This study is based on the idea that people who tolerated MK-1406 well before will likely continue to tolerate it safely with repeated annual dosing, and that the risk of immune reactions will remain low.
The group in the trial
- MK-1406Treatment being tested
Participant will receive 450 mg dose of MK-1406 (CD388) by subcutaneous (SC) injection followed 1 year later by a repeat single 450 mg dose of MK-1406 administered by SC injection.
Treatment: MK-1406 Injection
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2, Open-Label, Long-Term Study to Evaluate the Safety, Pharmacokinetics, and Occurrence of Anti-Drug Antibodies in Healthy Participants Following Annual Doses of CD388, a Novel Long-Acting Antiviral Conjugate
- Record updated
- 20 August 2026